New hope for PNH patients: early access to danicopan combo therapy
NCT ID NCT05982938
First seen Jan 06, 2026 · Last updated May 10, 2026 · Updated 28 times
Summary
This program provides early access to danicopan for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have significant anemia despite current treatment with Soliris or Ultomiris. Participants must be at least 18 years old, have been on Soliris or Ultomiris for 6 months, and meet specific blood count criteria. The goal is to control disease by reducing red blood cell destruction outside blood vessels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.